A Disease to Be Treated or Market to Be Tapped? (Los Angeles Times)



An awareness campaign funded by a leading pharmaceutical and health care products company has men questioning whether they have low testosterone, or “Low T,” reports the Los Angeles Times. Dartmouth’s Lisa Schwartz and Steven Woloshin, whose commentary, the article notes, was recently published in JAMA Internal Medicine, question the motives of the campaign.

“Whether the campaign is motivated by a sincere desire to help men or simply by greed, we should recognize it for what it is: a mass, uncontrolled experiment that invites men to expose themselves to the harms of treatment unlikely to fix problems that may be wholly unrelated to testosterone levels,” write Schwartz and Woloshin, of The Dartmouth Institute for Health Policy & Clinical Practice (TDI), the newspaper notes.

“Before anyone makes millions of men aware of Low T, they should be required to do a large-scale randomized trial to demonstrate that testosterone therapy for healthy aging men does more good than harm,” write Schwartz and Woloshin, who are both co-directors of TDI’s Center for Medicine and Media.

Read the full story, published 8/13/13 by the Los Angeles Times.

Office of Communications